Cyxone
0.046 SEK -5.21%Be the first to follow this company
Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CYXO
Daily low / high price
0.044 / 0.056
SEK
Market cap
9.82M SEK
Turnover
266.16K SEK
Volume
5.5M
Financial calendar
Interim report
2024-08-29
Interim report
2024-11-07
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 5.8 % | 5.8 % |
Ivar Nordqvist | 4.2 % | 4.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Cyxone: Styrelsen beslutar om företrädesemission om högst cirka 23 MSEK för att finansiera fortsatt utveckling av rabeximod och T20K
Cyxone: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools